Hemab Therapeutics Holdings Inc（COAG）资讯与事件COAGHemab Therapeutics Holdings Inc

Hemab CEO Announces New Program HMB-003 Addressing Heavy Menstrual Bleeding

"This was a very productive quarter for Hemab with continued execution across our pipeline," said Benny Sorensen, CEO of Hemab. "We had a significant presence at ISTH 2026, presenting data from all our programs. The strong interest we saw in that data underscores both the significant unmet need in bleeding disorders and the potential for our clinical and preclinical pipeline to redefine the standard of care in this space. We are particularly pleased to announce a new program, HMB-003, where we are addressing heavy menstrual bleeding, an indication that affects millions of women globally. HMB-003 is another example of how Hemab is developing treatments that could redefine care across high-unmet-need bleeding disorders. We look forward to providing additional updates on our programs later this year."

Hemab Therapeutics Presents HMB-002 Clinical Data

Hemab Therapeutics presented new clinical data from HMB-002 in Von Willebrand disease, VWD, and announced the HMB-003 program at the International Society on Thrombosis and Haemostasis, ISTH, 2026 Congress in Paris, France. HMB-002 is designed to address the underlying biological drivers of VWD through a non-replacement approach-elevating the body's endogenous levels of VWF and FVIII rather than infusing exogenous factor-with early first-in-human data building a compelling case for this paradigm shift. Extended half-life supporting infrequent dosing: Pharmacokinetic analysis confirmed dose-dependent increase in Cmax with prolonged duration. Dual VWF and FVIII elevation: In all dose cohorts tested, VWF and FVIII were elevated in a dose-dependent manner. In cohort A3, greater than or equal to2.4-fold elevation in both VWF and FVIII was achieved and accompanied by restoration of thrombin generation, shortening of APTT, and stable multimer distribution. Emerging safety profile: Most treatment-emergent adverse events were mild to moderate in severity, no serious TEAEs occurred, no events were considered related to HMB-002, and no participant discontinued the study due to TEAEs. Preliminary clinical observations: The single ascending dose part of the study wasn't designed to measure efficacy, so clinical observations should be considered descriptive in nature. HMB-003 is a novel fatty-acid-conjugated peptide antifibrinolytic, designed to stabilize clots and reduce bleeding across multiple settings, beginning in heavy menstrual bleeding, with preclinical data supporting potent, selective antifibrinolytic activity and extended duration of action. Potent and selective plasmin inhibition: HMB-003 directly inhibits plasmin at its active site and inhibits fibrinolysis across both tPA- and uPA-driven pathways, while showing no effect on thrombin generation, platelet function, or coagulation in nonclinical studies. Extended antifibrinolytic activity: Following a single subcutaneous dose in minipigs, HMB-003 achieved peak plasma levels within hours and sustained antifibrinolytic activity for approximately one week, supporting the potential for cycle-matched dosing in heavy menstrual bleeding.

SpaceX Files for IPO Aiming to Raise $80 Billion

SpaceX and OpenAI are moving toward blockbuster public debuts, with SpaceX formally filing its Form S 1 to list on Nasdaq under the ticker "SPCX" in what could become the largest IPO in history. Meanwhile, OpenAI is reportedly preparing to submit its own draft prospectus as early as this week for a potential September listing.LATEST IPOS AND DIRECT LISTINGS:Conexeu Sciencesopened on May 21 at $13.50 after a Nasdaq direct listing. The preclinical developer of a regenerative tissue device for wound care and aesthetics filed a resale prospectus with the SEC stating that it expected its common stock to begin trading on the Nasdaq on or about Thursday, May 21, in connection with its direct listing. The company registered 9.5M shares that may be sold by the Registered Securityholders identified in the prospectus. Conexeu Sciences will not raise new capital in its listing. The stock opened for trading earlier at a price of $13.50 per share.Lincoln Internationalopened on May 20 at $22.51. The company priced 21.05M shares at $20.00, at the top end of the $18.00-$20.00 target range. Lincoln International is an investment banking advisor whose services include mergers and acquisitions advisory, private funds and capital markets advisory, and valuations and fairness opinions.Amass Brandsopened on May 20 at $17 after a Nasdaq direct listing. The premium, multi-category beverage platform spanning non-alcohol, functional, and alcohol 2.0 products saw its common stock begin trading earlier on the Nasdaq Capital Market under the stock ticker symbol "AMSS". The direct listing did not involve the issuance of new common stock by the company, it noted.Optimi Healthopened on May 20 at $5.50 after a Nasdaq uplisting. The commercial-stage pharmaceutical company focused on manufacturing and distributing finished psychedelic drug products announced the pricing of its underwritten public offering in connection with the uplisting of its common shares to the Nasdaq Capital Market. The company offered 2.4M common shares at a public offering price of $6.25 per share.RECENT SPAC IPOS:Peace Acquisitionopened on May 22 at $10.01. The blank check company intends to focus its search on businesses throughout Asia. "However, the Company will not undertake an initial business combination with any entity based in or with its principal business operations in Mainland China, Hong Kong or Macau," it added.Aperture ACopened on May 21 at $10.01. The blank check company was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.Research Alliance Corporation IIIopened on May 20 at $10.21. The blank check company intends to focus its search on a target business in the healthcare or healthcare-related industries.Amanat Acquisitionopened on May 19 at $10.15. While the company may pursue an initial business combination target in any business or industry, it intends to focus on opportunities in healthcare or healthcare-related industries.PERFORMANCE:Prices as of 10:15 am ET on Monday, May 26 -Conexeu Sciences – down about 5% at $13.70;Lincoln International – down more than 2% at $23.52;Amass Brands – down almost 11% at $3.85;Optimi Health – down about 5% at $5.57.RECENT IPOS TO WATCH:Pershing Square Inc., Pershing Square USA, Avalyn Pharma, Hemab Therapeuticsand Seaport Therapeuticsare already seeing coverage roll out, while Silver Bow Miningis among stocks that could see new coverage this week as the quiet periods for banks that underwrote the companies' IPOs expire.UPCOMING IPOS:Upcoming IPO and direct listings expected include SpaceX, Sunshine Silver Mining & Refining, Innio, Inspire Brands, and Tarsier Pharma.Clickto see upcoming IPO calendar on TipRanks.SpaceXofficially submitted its Form S-1 with the SEC to list its Class A common stock on the Nasdaq under the ticker symbol SPCX. Expected to be the largest IPO in history, the company targets raising up to $80B at a valuation exceeding $2T.Sunshine Silver Mining & Refining Companyannounced the launch of its initial public offering of 20M shares of its common stock. In connection with the offering, Sunshine expects to grant the underwriters a 30-day option to purchase up to 3,000,000 shares of common stock. The IPO price is expected to be between $13.50-$16.50 per share. Sunshine's common stock has been approved for listing, subject to official notice of issuance, under the ticker symbol "SSMR" on the New York Stock Exchange.Innioannounces that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common shares. The timing of the offering, number of shares to be offered and the price range for the proposed offering have not yet been determined. Innio has applied to list its common shares on the Nasdaq Global Select Market under the ticker symbol "INIO." Innio designs, manufactures and services power systems under its Jenbacher and Waukesha brands. The company delivers power for applications including data centers, microgrids, grid stabilization, industrial energy and gas compression.Inspire Brandsannounced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. Inspire Brands expects to use the net proceeds of the proposed offering to repay outstanding indebtedness under its existing term loan facility and pay offering fees and expenses.Tarsier Pharma Ltd.filed for an initial public offering of its ordinary shares and applied to list its ordinary shares on the NYSE American under the symbol "TARX". The prospectus stated: "Tarsier Pharma is developing TRS01 and TRS02, novel product candidates based on dazdotuftide, a new molecule with a new mechanism of action for uveitis and uveitic glaucoma. We are attempting to address a significant, underserved market opportunity and have engaged closely with the FDA on our clinical development strategy, including a Special Protocol Assessment agreement for our planned pivotal trial."OTHER IPO NEWS:OpenAI is preparing to file for a public listing as early as this week, with the AI lab aiming for a blockbuster initial public offering as soon as September, Financial Times' George Hammond. The company has been laying the groundwork for an offering expected to value it at north of $1T, working with bankers at Morgan Stanleyand Goldman Sachsand lawyers at Cooley over the past few months, according to people familiar with the matter. The group could file a draft IPO prospectus as early as Friday, starting the timer on a public listing for the autumn, they added. That timing could shift depending on the market and on the performance of Elon Musk's SpaceX, which is expected to go public next month in the biggest listing of all time, the author notes.Opening Day" is The Fly's recurring series of stories on the latest initial public offerings, their performance, and upcoming IPOs.